Case Control Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 14, 2015; 21(14): 4240-4247
Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4240
Table 1 Methyl-methanesulfonate sensitivity 19 expression n (%)
TissueCases (n)Cytoplasmic expression
P valueNuclear expression
P value
HighLowHighLow
NESE528 (15.4)44 (84.6)< 0.00136 (69.2)16 (30.8)< 0.001
ESCC10365 (63.1)38 (36.9)36 (35.0)67 (65.0)
Table 2 Associations of MMS19 expression with clinicopathologic features of esophageal squamous cell carcinoma
CharacteristicCases (n)Cytoplasmic MMS19
Nuclear MMS19
HighLowP valueHighLowP value
Total10365383667
Sex
Male8455290.29532520.159
Female19109415
Age (yr)
< 553318150.21614190.275
≥ 557047232248
Site
Upper thoracic10730.686280.508
Middle thoracic4731161631
Lower thoracic4627191828
Differentiation
Well201370.7856140.871
Moderate5234181933
Poor3118131120
TNM stage
I + II2714130.1588190.500
III + IV7651252848
Invasion depth
T1 + T2251780.5607180.402
T3 + T47848302949
LNM
No12210< 0.001480.900
Yes9163283259
DM
No8548370.00232530.212
Yes18171414
Table 3 Clinical features of patients receiving neoadjuvant chemoradiotherapy followed by surgery, n
CharacteristicGood responsePoor responseP value
(n = 29)(n = 20 )
Age (yr)
< 5511110.238
≥ 55189
Sex
Male24150.763
Female55
Tumor size (cm)
< 51270.652
≥ 51713
Site
Upper thoracic320.405
Middle thoracic146
Lower thoracic1212
Differentiation
Well540.936
Moderate1610
Poor86
TNM stage
IIb860.857
III2114
Cytoplasm
High235< 0.001
Low615
Nucleus
High990.319
Low2011